What Happened?
Washington, DC-based Regenxbio Appointed Vit Vasista as Chief Financial Officer
Date of management change: May 20, 2015
Washington, DC-based Regenxbio Appointed Vit Vasista as Chief Financial Officer
Regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. Regenxbio`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on Regenxbio`s NAV Technology Platform. Regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Vit Vasista is the Chief Financial Officer and Senior Vice President of Corporate Development at REGENXBIO. Prior to joining REGENXBIO, Mr. Vasista served as Principal at PRTM Management Consultants, where he developed operational strategies for both private and public organizations, including the development of market entry strategies, innovative business models, and operational improvements.
Company Announcement
Other IT executives who recently changed jobs as well: Bongiovi Joseph, Cushing Laura, Alexander Gena, Chan Charlene, Rowden Jill, Draeger Jay, Whitehead Beth, Madhavan Anand, Rosenberry Lori, Bonanno Kathy, Jacobs Alicia
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.